“SRI is pleased to be awarded this important contract to conduct the preclinical safety studies needed to understand whether a compound can eventually be administered to people,” said Hanna Ng, Ph.D., director of preclinical safety, SRI International, and principal investigator for the program. “Our multidisciplinary team has experience in safety evaluation and regulatory compliance needed to effectively support the NIMH’s preclinical development program for central nervous system imaging agents and therapeutics for various mental disorders.”
SRI International is an independent nonprofit research and development organization.
